Lux Capital

Versant Ventures is a prominent venture capital firm based in New York, specializing in harnessing the power of science to deliver strong results in the biotechnology sector since 1999. With a seasoned team boasting over 100 years of combined venture capital experience and extensive backgrounds in pharma and biotech, the firm actively fosters innovation through its multidisciplinary discovery engines. Operating from six locations, Versant Ventures partners with academic institutions to launch novel biotechnology companies, leveraging state-of-the-art laboratory facilities and a robust network of over 30 academic partnerships. This strategic approach positions the firm at the forefront of scientific discoveries and advancements in the healthcare landscape. Generated from the website

IA Ventures is a venture capital firm located in the heart of New York City. With their office situated on the 15th floor of 920 Broadway, they are strategically positioned to invest in and support innovative startups. As a leading player in the venture capital industry, IA Ventures focuses on early-stage investments in data-driven companies. Their diverse portfolio showcases their expertise in areas such as artificial intelligence, machine learning, and data analytics.Generated from the website

New Leaf Venture Partners' objectives with each investment are to back a strong, entrepreneurial management team, to provide appropriate financial resources, to help build a great company, and to create exceptional equity value. We are active investors and almost always serve as directors of our portfolio companies, who can draw upon perspectives and experiences of the entire NLV investment team and its network of successful scientists, clinicians, operating executives and entrepreneurs. We assist in building management teams, guiding corporate strategy, providing input to operating plans, and in making decisions about optimal paths for future financings and exits. As conditions evolve, NLV Partners team continually refines its differentiated strategy in healthcare investing. Both of NLV's latest funds, New Leaf Ventures I and New Leaf Ventures II, focus on taking leadership positions in: Biopharmaceuticals - NLV has an in-depth understanding of therapeutic targets and modalities, the drug R&D process, clinical trial design, regulatory requirements, and pharmaceutical commercial activities. NLV's extensive medical, clinical development, commercial and financial experience helps companies navigate the challenging path to regulatory approval and commercialization as stand-alone companies or through value-added strategic partnerships. NLV invests in companies at all stages in this sector, but looks at the level of risk, costs, and timelines to build real value in the underlying program (s) in determining if an investment fits our strategy. NLV has been particularly active in starting and investing in companies that been formed around the spin out of programs from larger pharmaceutical and biotech companies. Medical devices - NLV works closely with its network of entrepreneurs and scientific and medical founders to identify investment opportunities around promising technologies targeting areas of high unmet medical need and large commercial potential. The current strategy is to focus on later stage opportunities to provide growth capital or the last round to profitability in which regulatory and reimbursement risks are minimal. NLV will invest in early stage companies when there are large established global markets and an opportunity to prove safety and effectiveness in a focused, cost effective program. NLV's investment team brings critical operating experience and the ability to evaluate the biological, engineering, regulatory, reimbursement and market risks most relevant to starting, growing, developing and exiting young or more mature companies in the medical devices sector.